IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology

Background Intravenous immunoglobulin (IVIg) is currently in clinical study for Alzheimer’s disease (AD). However, preclinical investigations are required to better understand AD-relevant outcomes of IVIg treatment and develop replacement therapies in case of unsustainable supply.